Quest's Haystack Acquisition Faces Technology Validation Risk That Could Derail Deal
Quest Diagnostics' pending acquisition of Haystack Oncology carries catastrophic deal failure risk if the liquid biopsy company's technology doesn't meet validation expectations. The deal could collapse or face repricing if Haystack's minimal residual disease detection platform underperforms during due diligence. Quest's financial constraints pose an additional termination risk.
ViaNews Editorial Team (Markets)•